Kinalska I, Siewko K. The role of glimepiride in the treatment of type 2 diabetes with cardiovascular disease. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review. 2007:179-183.
APA
Kinalska, I., & Siewko, K. (2007). The role of glimepiride in the treatment of type 2 diabetes with cardiovascular disease. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, 179-183.
Chicago
Kinalska, Ida, and Katarzyna Siewko. 2007. "The role of glimepiride in the treatment of type 2 diabetes with cardiovascular disease". Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review: 179-183.
Harvard
Kinalska, I., and Siewko, K. (2007). The role of glimepiride in the treatment of type 2 diabetes with cardiovascular disease. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, pp.179-183.
MLA
Kinalska, Ida et al. "The role of glimepiride in the treatment of type 2 diabetes with cardiovascular disease." Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review, 2007, pp. 179-183.
Vancouver
Kinalska I, Siewko K. The role of glimepiride in the treatment of type 2 diabetes with cardiovascular disease. Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review. 2007:179-183.
Glimepiride is indicated for the treatment of type 2 diabetes mellitus. Many studies indicate that during treatment with glimepiride there is a reduction of HBA1C and BMI, low incidence of hypoglycaemia, and good tolerability and efficacy in patients with cardiovascular disease.
Keywords
diabetes mellitus type 2, glimepiride, cardiovascular disease